Drug intelligence / Profile preview

SRNDE-01

Development stage: Preclinical
Lead developer: Sirius Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

SRNDE-01 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Sirius Therapeutics (also known as Sirius Natural) for the treatment of complement disorders. The drug utilizes siRNA-mediated gene silencing technology to target a specific, currently undisclosed, component of the complement system. SRNDE-01 is designed for delivery using Sirius' proprietary delivery platform, which is capable of targeting tissues including the liver, adipose, heart, kidney, or central nervous system (CNS). The program is currently in the preclinical/IND-enabling stage of development.

Other names: Sirius Natural

Beyond the preview

Go deeper on SRNDE-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRNDE-01.